Stopping Bispecific Appears Safe in Relapsed/Refractory Myeloma

(MedPage Today) — TORONTO — A substantial proportion of multiple myeloma patients undergoing treatment with bispecific antibodies had sustained remissions when they discontinued therapy before disease progression, according to research presented…